Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
about
Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysisAdvancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Bone remodeling markers and bone metastases: From cancer research to clinical implicationsModelling circulating tumour cells for personalised survival prediction in metastatic breast cancerBone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the artPossible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trialsValue of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyEradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer.Treatment options for breast cancer and bone metastases.Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastasesA new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway.Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone.Zoledronic acid use in cancer patients: more than just supportive care?Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates.Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence.Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.Biomarkers of bone turnover in oncology: applications in diagnosis and treatment.The critical role of bisphosphonates to target bone cancer metastasis: an overview.N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine.RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
P2860
Q26861745-2D89C25A-F2F0-47D7-AE10-AB6AC55B4D3EQ30438167-489EA287-5A2F-46F4-AF8D-6FAFF4C709B9Q33563273-4904A5B5-946A-410A-9981-BE238C52F484Q33739204-B7C18A3B-98F5-45FC-B6D2-FEB621540E34Q34026943-C69CF0F6-C507-4939-AFD3-91592EAE3626Q34939979-341DD124-370C-4F73-82C7-CF08FDAE62CCQ34960867-734D2DB9-4310-41B2-BDCB-84FBD09F4C62Q35531006-1319642B-29C3-49D1-8631-90598B0F43F9Q35610546-8F0CD50F-965B-4B50-AF99-BE1051F8080EQ36278556-52688597-7879-4AE2-8418-BBF6E87AF0C0Q36491479-92460278-EA29-49B7-BA15-D933DEC3F89CQ36516278-97F30593-0F55-4A84-822F-071064A41045Q36959180-C9C7E556-6D97-4BCF-85D1-9A0F9785A459Q36959955-F0038063-D491-4C1F-B770-A7789A50BB44Q37007044-0CA6F307-8C3B-4923-BACC-F86155454C21Q37355362-4CB3823B-45FC-43B6-B7E5-38054F4389E6Q37401841-A1FBCD13-82CB-4E06-9749-24B05B049182Q37483543-6F1D6051-8341-4302-B6A8-7CC929D01891Q37728428-7A98B3B1-A87E-4EBE-9060-BE3605D42F2CQ37800179-8C7D745E-338D-4F43-B6F3-852AFAAFC1B4Q37828494-D861E4BA-CA4D-4143-AAF3-BD507448090DQ37830052-4E638902-668F-4628-A6AF-B201A6130989Q37845836-DC1C7BBA-0444-4E84-9895-EAC6C75A7C10Q38040123-38BA1483-957C-4E4C-BA27-354AF19ED6C3Q38088714-B624C2DC-4109-4424-AB1E-9C74B285ACDEQ38247428-7AFA7450-7F45-42AD-BA96-0583C722BD6BQ38830394-454093CB-425D-4847-94A5-D700686C8C3FQ41241592-0AE4AC49-2EFC-4CE9-BCEA-E79F1DC136C6Q43106531-B8F5D976-B25D-45A6-B8C8-200DECA84A98Q47146433-BF30B2F0-F6CC-45CB-B621-EF7A8DCCD061Q53130858-9FBB3DD3-DF10-46F3-8531-3198346051BBQ55096284-16019F05-DA47-4404-B1B8-FDB1D118D4CCQ57904702-C9636E0C-8D01-4870-A5AB-88691FE88188
P2860
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Zoledronic acid and survival i ...... arkers of osteoclast activity.
@en
Zoledronic acid and survival i ...... arkers of osteoclast activity.
@nl
type
label
Zoledronic acid and survival i ...... arkers of osteoclast activity.
@en
Zoledronic acid and survival i ...... arkers of osteoclast activity.
@nl
prefLabel
Zoledronic acid and survival i ...... arkers of osteoclast activity.
@en
Zoledronic acid and survival i ...... arkers of osteoclast activity.
@nl
P2093
P1433
P1476
Zoledronic acid and survival i ...... arkers of osteoclast activity.
@en
P2093
Allan Lipton
Matthew R Smith
Pierre Major
Richard J Cook
Robert E Coleman
P304
P356
10.1634/THEONCOLOGIST.12-9-1035
P577
2007-09-01T00:00:00Z